Advertisement

Cancer Chemotherapy and Pharmacology

, Volume 69, Issue 2, pp 407–413 | Cite as

A multicenter phase II study of combined chemotherapy with docetaxel, cisplatin, and S-1 in patients with unresectable or recurrent gastric cancer (KDOG 0601)

  • Wasaburo Koizumi
  • Norisuke Nakayama
  • Satoshi Tanabe
  • Tohru Sasaki
  • Katsuhiko Higuchi
  • Ken Nishimura
  • Seiichi Takagi
  • Mizutomo Azuma
  • Takako Ae
  • Kenji Ishido
  • Kento Nakatani
  • Akira Naruke
  • Chikatoshi Katada
Original Article

Abstract

Purpose

We conducted a phase II study to evaluate the efficacy and safety of a triplet regimen of docetaxel, cisplatin, and S-1 in patients with unresectable or recurrent gastric cancer.

Methods

Docetaxel (40 mg/m2) and cisplatin (70 or 60 mg/m2) were given on day 1 of a 28-day cycle. S-1 (40 mg/m2) was given twice daily on days 1–14. Treatment with this regimen was continued for a maximum of 6 cycles. Subsequently, patients with no disease progression received a combination of docetaxel and S-1.

Results

Fifty-nine patients were enrolled. The median number of administered cycles was 8 (range, 1–25). Because some patients had serious myelosuppression and renal dysfunction with 70 mg/m2 of cisplatin, dose of cisplatin was reduced to 60 mg/m2 after 19 patients had been treated. Common severe toxic effects of grade 3 or 4 were leukocytopenia (44%), neutropenia (72%), anemia (15%), and febrile neutropenia (14%). The overall response rate of this group was 81% (95% confidence interval (CI), 71–91%). The median overall survival and progression-free survival were 18.5 (95% CI, 15.6–21.5) and 8.7 (95% CI, 6.7–10.7) months, respectively.

Conclusions

Triplet of docetaxel, cisplatin, and S-1 is a well-tolerated and highly active regimen for advanced or recurrent gastric cancer. A 60 mg/m2 of cisplatin is as effective as 70 mg/m2 of cisplatin.

Keywords

Docetaxel Cisplatin S-1 (combination) Gastric cancer Phase II 

Notes

Acknowledgments

The Authors thank Nobutaka Samejima, Satoshi Matsumoto and Ryouta Seto for their helpful advices.

Conflict of interest

None.

References

  1. 1.
    Kamangar F, Dores GM, Anderson WF (2006) Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 24(14):2137–2150PubMedCrossRefGoogle Scholar
  2. 2.
    Munoz N, Franceschi S (1997) Epidemiology of gastric cancer and perspectives for prevention. Salud Publica Mex 39(4):318–330PubMedGoogle Scholar
  3. 3.
    Ministry of Health Law. Vital Statistics of Japan (2009)Google Scholar
  4. 4.
    Shirasaka T, Shimamato Y, Ohshimo H, Yamaguchi M, Kato T, Yonekura K et al (1996) Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs 7(5):548–557PubMedCrossRefGoogle Scholar
  5. 5.
    Boku N, Yamamoto S, Fukuda H, Shirao K, Doi T, Sawaki A et al (2009) Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study. Lancet Oncol 10(11):1063–1069PubMedCrossRefGoogle Scholar
  6. 6.
    Koizumi W, Narahara H, Hara T, Takagane A, Akiya T, Takagi M et al (2008) S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol 9(3):215–221PubMedCrossRefGoogle Scholar
  7. 7.
    Ajani JA, Rodriguez W, Bodoky G, Moiseyenko V, Lichinitser M, Gorbunova V et al (2010) Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial. J Clin Oncol 28(9):1547–1553PubMedCrossRefGoogle Scholar
  8. 8.
    Van Cutsem E, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C et al (2006) Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 study group. J Clin Oncol 24(31):4991–4997PubMedCrossRefGoogle Scholar
  9. 9.
    Nakayama N, Koizumi W, Sasaki T, Higuchi K, Tanabe S, Nishimura K et al (2008) A multicenter, phase I dose-escalating study of docetaxel, cisplatin and S-1 for advanced gastric cancer (KDOG0601). Oncology 75(1–2):1–7PubMedCrossRefGoogle Scholar
  10. 10.
    Yoshida K, Ninomiya M, Takakura N, Hirabayashi N, Takiyama W, Sato Y et al (2006) Phase II study of docetaxel and S-1 combination therapy for advanced or recurrent gastric cancer. Clin Cancer Res 12:3402–3407PubMedCrossRefGoogle Scholar
  11. 11.
    Yamaguchi K, Shimamura T, Hyodo I, Koizumi W, Doi T, Narahara H et al (2006) Phase I/II study of docetaxel and S-1 in patients with advanced gastric cancer. Br J Cancer 94(12):1803–1808PubMedCrossRefGoogle Scholar
  12. 12.
    Fujii M (2008) Chemotherapy for advanced gastric cancer: ongoing phase III study of S-1 alone versus S-1 and docetaxel combination (JACCRO GC03 study). Int J Clin Oncol 13(3):201–205PubMedCrossRefGoogle Scholar
  13. 13.
    Sato Y, Takayama T, Sagawa T, Takahashi Y, Ohnuma H, Okubo S et al (2010) Phase II study of S-1, docetaxel and cisplatin combination chemotherapy in patients with unresectable metastatic gastric cancer. Cancer Chemother Pharmacol 66:721–728Google Scholar
  14. 14.
    Al-Refaie WB, Tseng JF, Gay G, Patel-Parekh L, Mansfield PF, Pisters PWT, Yao JC, Feig BW (2008) The impact of ethnicity on the presentation and prognosis of patients with gastric adenocarcinoma. Cancer 113:461–469PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2011

Authors and Affiliations

  • Wasaburo Koizumi
    • 1
  • Norisuke Nakayama
    • 2
  • Satoshi Tanabe
    • 1
  • Tohru Sasaki
    • 1
  • Katsuhiko Higuchi
    • 1
  • Ken Nishimura
    • 2
  • Seiichi Takagi
    • 2
  • Mizutomo Azuma
    • 1
  • Takako Ae
    • 1
  • Kenji Ishido
    • 1
  • Kento Nakatani
    • 3
  • Akira Naruke
    • 1
  • Chikatoshi Katada
    • 3
  1. 1.Department of Gastroenterology/Gastrointestinal OncologyKitasato University East HospitalSagamihara, KanagawaJapan
  2. 2.Division of GastroenterologyKanagawa Cancer CenterKanagawaJapan
  3. 3.Department of GastroenterologyKitasato University HospitalKanagawaJapan

Personalised recommendations